Chadé Severin represents private and public companies on a wide range of corporate and securities law matters, including mergers and acquisitions, securities law compliance and other general corporate matters.

Ms. Severin’s representations include:

  • Stemline Therapeutics in its sale to Menarini Group for up to $677 million;
  • Gilead Sciences in its $4.9 billion acquisition of Forty Seven;
  • ArQule in its sale to Merck for $2.7 billion;
  • Carbonite in its sale to OpenText for $1.42 billion;
  • Achillion in its sale to Alexion for up to $1.225 billion;
  • Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion;
  • Array BioPharma in its $11.4 billion sale to Pfizer;
  • Carbonite in its $618.5 million acquisition of Webroot;
  • Armstrong Flooring Inc. in the sale of its wood flooring business to American Industrial Partners;
  • Juno Therapeutics in its $9 billion acquisition by Celgene;
  • Ultragenyx in its successful topping bid for Dimension Therapeutics;
  • Gilead in its $11.9 billion acquisition of Kite Pharma;
  • Merrimack Pharmaceuticals in its asset sale to Ipsen S.A. for up to $1.025 billion;
  • Tobira Therapeutics in its acquisition by Allergan for up to $1.7 billion; and
  • Qlik Technologies in its $3 billion acquisition by Thoma Bravo.

Before attending law school, Ms. Severin worked for Google at its California headquarters.



  • J.D., Columbia Law School, 2013
  • B.A., Stanford University, 2007


  • Massachusetts
  • New York

Chadé Severin

Associate, Mergers and Acquisitions